Business Wire

Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables

Share

New global research,2 sponsored by Galderma and released today by leading filler brand Restylane®, has revealed the prevalent societal misconceptions and stereotypes facing the aesthetics industry. Forty percent of respondents admitted they would discourage others from using facial injectables to reduce wrinkles or provide volume. A further 34% said they believed the results of such treatments look fake and unnatural.

Despite holding these views, when the same respondents were presented with a range of images of people who had undergone filler treatments, the data told another story. On average, 4 out of 5 people could not always identify those who had received filler.3 This highlights the common misconceptions about these types of treatments and the results they deliver.

The perceptions surrounding the use of temporary fillers stand in stark contrast to those around the use of permanent beauty treatments such as tattoos, body piercings and dental corrections. Tattoos and body piercings are primarily seen as a positive form of self-expression (30% of respondents agreed for tattoos, and 24% for body piercings). Teeth straightening is viewed by 47% of respondents as a great way to enhance your appearance. Meanwhile, over a third of respondents (35%) believe fillers create unrealistic beauty standards and ideals, while 26% feel they can easily become addictive and 24% say they are an extreme option.

However, Restylane patient feedback data shows that 96% of people who used fillers felt their treatment exceeded expectations,4 and 95% of patients had maintained or enhanced the naturalness of their facial expressions after treatment.5,6

 

“This new research by Restylane highlights the perception that people are choosing procedures such as fillers because they lack confidence or are going to extremes to get their desired look. But this just isn’t the case! The vast majority of the clients I see are opting for small, subtle changes that will help them create their own look and feel empowered to be the best version of themselves. In my opinion, these people are inherently self-confident, know their own minds and are simply taking control of their own looks.”

 

DR. LUIZ AVELAR

PLASTIC SURGEON

BELO HORIZONTE, BRAZIL

 

The prevalence of societal judgements and the impact they have on how people behave are laid bare in the study. Only 11% of respondents said they would be supportive if a friend or family member told them they were considering using fillers. In contrast, according to Restylane patient feedback, 99% of those who have received treatment would recommend Restylane to a friend.4,6

Media leads in debunking misconceptions

The results also reveal that people see the media as more progressive in its views about aesthetic treatments. 27% percent of respondents said the media portrays injectables as empowering, while just 13% would personally describe them this way. Adult Gen Z7 respondents displayed a more open-minded attitude toward aesthetic procedures and were more likely to see treatments of this nature as empowering (19% in this age group agreed versus 13% overall). They were almost three times more likely to feel positively toward fillers than those over 55 years old, only 7% of whom agreed. Younger consumers also feel that people seeking injectable treatments are inherently more confident.

 

“I’m finding the newer generation is even more open-minded and interested when it comes to injectables. They consider aesthetic treatments to further define and enhance how they look and feel. Given that Restylane studies show that those who use dermal fillers feel overwhelmingly positive about their treatment, we are likely to see more people using them as a means of empowerment.”

 

STEVEN DAYAN, M.D.

FACIAL PLASTIC SURGEON, PROFESSOR AND DIRECTOR OF DENOVA RESEARCH

CHICAGO, ILLNOIS, U.S.

 

The research appears ahead of a Restylane product placement spot in new action-comedy film Mafia Mamma, directed by Catherine Hardwicke of Twilight fame and co-starring Toni Collette and Monica Bellucci. Mafia Mamma celebrates female empowerment and sees Toni Collette’s character challenging her comically clueless colleagues and their outdated attitudes about the reasons why women chose to undergo aesthetic treatments. While the film uses humor to highlight these stereotypes and the judgements people make about injectables, the attitudinal study highlights how these real-life judgements are still prevalent in society. Such beliefs have a tangible impact on the way people behave toward those considering fillers.

 

“We believe in championing everybody’s right to pursue their own beauty ideals. Our research findings are shining a spotlight on some of the misconceptions people have about aesthetic treatments. In this way, we hope to better equip people to make the decision that is right for them, without worrying about external pressures and judgements.”

 

GERRY MUHLE

HEAD OF GLOBAL BUSINESS UNIT, AESTHETICS

GALDERMA

 

About Restylane®

Restylane is the original non-animal stabilized hyaluronic acid filler with over 26 years of achievement and over 55 million treatments worldwide. NASHA™ and OBT™ technologies make Restylane the world’s most diverse range of fillers to deliver truly individualized results.4,5

The Restylane portfolio of products includes Restylane, Restylane Lyft, Restylane Kysse, Restylane Volyme, Restylane® Defyne, Restylane® Refyne, Restylane® EYELIGHT, Restylane SKINBOOSTERS VITAL and Restylane SKINBOOSTERS VITAL LIGHT.

About Galderma

Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information, visit: www.galderma.com.

Footnotes
1 Injectables are aesthetic products which are injected under the skin for a variety of reasons. These include relaxing muscles to alleviate facial wrinkles and folds, or helping contour areas of the face or body, e.g., by restoring volume or adding projection. They often come in the form of products such as botulinum toxin or HA-fillers.
2 Research was carried out by YouGov surveying 9,733 people across the UK, U.S., Canada, Brazil, Germany and Thailand between January 17 and 27, 2023.
3 Respondents were shown six images of people who had used dermal fillers and were asked to indicate if they think the person in the image had used dermal fillers.
4 Andriopoulos B, et al. Presented at: AMWC Monte Carlo, Monaco. 2019.
5 Phillipp-Dormston W, et al. J Cosmet Dermatol. 2020;19:1600–6.
6 Hilton S, et al. Dermatol Surg. 2018;44:261–9.6
7 Adult Gen Z includes those in the 18-24 age bracket.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Corporate Communications Director
Sebastien.cros@galderma.com
+41 79 529 59 85

Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 13:45:00 EEST | Press release

As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Prague, Czech Republic, the findings highlight the role of QbCheck, Qbtech’s remote testing solution, in enabling clinicians to make more confident, data-informed decisions, supporting a more personalized and collaborative care model. The tool allows for greater clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and helping to improve alignment between clinicians and patients throughout the care journey. The results from ADHD 360’s implementation of this model showcase how a standardized approach to virtual ADHD care improves clinician confidence, reduces wait times, and enhances patient engageme

Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 16:57:00 EEST | Press release

Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model and improve its predictions over time. The TST Model now forecasts the company's cashflow and FX exposure on an hourly, daily and weekly basis, w

Monument Re Transfers €1.4bn Greycastle Portfolio to RGA and Strengthens European Life Insurance Consolidation Platform9.5.2025 15:00:00 EEST | Press release

Monument Re Limited (“Monument”) announces today that it has transferred a legacy €1.4bn reinsurance portfolio, comprising annuity and other life insurance liabilities acquired as part of the 2020 Greycastle transaction, to RGA Americas Reinsurance Company, Ltd. (“RGA”). This transaction releases capital resources that Monument will redirect to its core strategy of consolidation in European life insurance markets. The transaction completed on 2May 2025 following approval by the Boards of Directors of both Monument and RGA and non-objection from the Bermuda Monetary Authority. Monument has taken significant steps in recent months to strengthen its business operations by consolidating its European group support functions in Dublin and by aligning with the recently strengthened regulatory regime in Bermuda. With its strong financial position and best in class capabilities in the Group, Monument remains ideally positioned to build on its success to date and grow its European footprint, del

IFF Completes Divestiture of Nitrocellulose Business9.5.2025 15:00:00 EEST | Press release

IFF (NYSE: IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF’s Pharma Solutions business unit. “The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses,” said Erik Fyrwald, IFF CEO. “I’d like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Le

CPAC Systems AB Announces Strategic Minority Investment in Flying Fish9.5.2025 13:33:00 EEST | Press release

CPAC Systems AB, a leader in advanced control systems and embedded vessel and commercial vehicle technology, today announced a strategic minority investment in Flying Fish Maritime Innovations B.V., a pioneer in advanced shared water mobility solutions and robust, cost-effective hydrofoil technology. The investment underscores both companies’ commitment to redefining water-based transportation through innovation, sustainability, and seamless integration. It marks the beginning of a deeper collaboration aimed at enabling smarter, cleaner, and more connected mobility on the water — for both recreational and commercial applications. “We are thrilled to support Flying Fish and their impressive work in redefining water mobility,"saidMarcus Wingolf, CEO of CPAC Systems. "Our investment in Flying Fish represents a strategic alignment of our technical proficiencies and innovative ambitions. This partnership opens exciting new possibilities for integration and sustainable transformation across

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye